Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes

Steven A. Rosenberg, Mark E. Dudley

Research output: Contribution to journalArticle

Abstract

Our recent clinical trials demonstrate that autologous cell transfer after lymphodepleting chemotherapy can cause the regression of large, vascularized tumors in patients with refractory metastatic melanoma. Eighteen of 35 patients treated with tumor-reactive lymphocyte cultures experienced an objective clinical response (>50% reduction in tumor), including four complete responders. In some patients, tumor regression was accompanied by a large in vivo expansion of the administered antitumor lymphocytes, which persisted in peripheral blood at >70% of total lymphocytes for many months after transfer. The cells capable of mediating tumor regression consisted of heterogeneous lymphocyte populations with high avidity for tumor antigens that were derived from tumor-infiltrating lymphocytes cultured for limited times in vitro. The success of this treatment likely results from the ability to infuse large numbers of activated antitumor lymphocytes into an appropriate host homeostatic environment depleted of regulatory T cells. These studies are elucidating the requirements for successful immunotherapy of patients with advanced metastatic disease and are leading to additional clinical trials with gene-modified lymphocytes.

Original languageEnglish (US)
Pages (from-to)14639-14645
Number of pages7
JournalProceedings of the National Academy of Sciences of the United States of America
Volume101
Issue numberSUPPL. 2
DOIs
StatePublished - Oct 5 2004
Externally publishedYes

Fingerprint

Melanoma
Lymphocytes
Neoplasms
Clinical Trials
Tumor-Infiltrating Lymphocytes
Neoplasm Antigens
Regulatory T-Lymphocytes
Immunotherapy
Drug Therapy
Population
Genes
Therapeutics

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. / Rosenberg, Steven A.; Dudley, Mark E.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 101, No. SUPPL. 2, 05.10.2004, p. 14639-14645.

Research output: Contribution to journalArticle

@article{f10422d1c4bf484e80a5b9c8a00a7812,
title = "Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes",
abstract = "Our recent clinical trials demonstrate that autologous cell transfer after lymphodepleting chemotherapy can cause the regression of large, vascularized tumors in patients with refractory metastatic melanoma. Eighteen of 35 patients treated with tumor-reactive lymphocyte cultures experienced an objective clinical response (>50{\%} reduction in tumor), including four complete responders. In some patients, tumor regression was accompanied by a large in vivo expansion of the administered antitumor lymphocytes, which persisted in peripheral blood at >70{\%} of total lymphocytes for many months after transfer. The cells capable of mediating tumor regression consisted of heterogeneous lymphocyte populations with high avidity for tumor antigens that were derived from tumor-infiltrating lymphocytes cultured for limited times in vitro. The success of this treatment likely results from the ability to infuse large numbers of activated antitumor lymphocytes into an appropriate host homeostatic environment depleted of regulatory T cells. These studies are elucidating the requirements for successful immunotherapy of patients with advanced metastatic disease and are leading to additional clinical trials with gene-modified lymphocytes.",
author = "Rosenberg, {Steven A.} and Dudley, {Mark E.}",
year = "2004",
month = "10",
day = "5",
doi = "10.1073/pnas.0405730101",
language = "English (US)",
volume = "101",
pages = "14639--14645",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes

AU - Rosenberg, Steven A.

AU - Dudley, Mark E.

PY - 2004/10/5

Y1 - 2004/10/5

N2 - Our recent clinical trials demonstrate that autologous cell transfer after lymphodepleting chemotherapy can cause the regression of large, vascularized tumors in patients with refractory metastatic melanoma. Eighteen of 35 patients treated with tumor-reactive lymphocyte cultures experienced an objective clinical response (>50% reduction in tumor), including four complete responders. In some patients, tumor regression was accompanied by a large in vivo expansion of the administered antitumor lymphocytes, which persisted in peripheral blood at >70% of total lymphocytes for many months after transfer. The cells capable of mediating tumor regression consisted of heterogeneous lymphocyte populations with high avidity for tumor antigens that were derived from tumor-infiltrating lymphocytes cultured for limited times in vitro. The success of this treatment likely results from the ability to infuse large numbers of activated antitumor lymphocytes into an appropriate host homeostatic environment depleted of regulatory T cells. These studies are elucidating the requirements for successful immunotherapy of patients with advanced metastatic disease and are leading to additional clinical trials with gene-modified lymphocytes.

AB - Our recent clinical trials demonstrate that autologous cell transfer after lymphodepleting chemotherapy can cause the regression of large, vascularized tumors in patients with refractory metastatic melanoma. Eighteen of 35 patients treated with tumor-reactive lymphocyte cultures experienced an objective clinical response (>50% reduction in tumor), including four complete responders. In some patients, tumor regression was accompanied by a large in vivo expansion of the administered antitumor lymphocytes, which persisted in peripheral blood at >70% of total lymphocytes for many months after transfer. The cells capable of mediating tumor regression consisted of heterogeneous lymphocyte populations with high avidity for tumor antigens that were derived from tumor-infiltrating lymphocytes cultured for limited times in vitro. The success of this treatment likely results from the ability to infuse large numbers of activated antitumor lymphocytes into an appropriate host homeostatic environment depleted of regulatory T cells. These studies are elucidating the requirements for successful immunotherapy of patients with advanced metastatic disease and are leading to additional clinical trials with gene-modified lymphocytes.

UR - http://www.scopus.com/inward/record.url?scp=5144226237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5144226237&partnerID=8YFLogxK

U2 - 10.1073/pnas.0405730101

DO - 10.1073/pnas.0405730101

M3 - Article

C2 - 15381769

AN - SCOPUS:5144226237

VL - 101

SP - 14639

EP - 14645

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - SUPPL. 2

ER -